Beacon will be attending Advanced Therapies USA in Philadelphia this week! Please reach out if you want to connect with our team there. Tom Biancardi Amy Adelman House Darin Curtiss Amy Christenson Tristan Martin #adtherapiesUSA #advancedtherapies #genetherapy
关于我们
Beacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to save and restore the vision of patients with a range of prevalent and rare retinal diseases that result in blindness. The Company has an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP), as well as two preclinical programs, one targeting dry age-related macular degeneration (AMD) and another targeting cone-rod dystrophy (CRD), an inherited retinal disease. Lead development candidate AGTC-501, is a gene therapy program in Phase II clinical trials for the treatment of XLRP, an inherited monogenic recessive disorder that causes progressive vision loss in boys and young men. XLRP is predominantly caused by mutations in the retinitis pigmentosa GTPase regulator (RPGR) gene. AGTC-501 expresses the full length RPGR protein, thereby addressing the full complement of photoreceptor damage caused by XLRP, including both rod and cone loss. Beacon Therapeutics also has access to a target generation technology platform that will identify, screen, and search secreted proteins in the ophthalmology space. The Company is supported by funds from Syncona, Forbion, Oxford Science Enterprises, TCGX, Advent Life Sciences and additional investors.
- 网站
-
https://www.beacontx.com/
Beacon Therapeutics的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Alachua，Florida
- 类型
- 私人持股
- 创立
- 2023
地点
Beacon Therapeutics员工
动态
-
Beacon Therapeutics is attending the European Society of Gene and Cell Therapy (ESGCT) Annual Congress in La Nuvola, Rome October 22-25. Please reach out to connect with our team members representing Beacon at the meeting. Azadeh Kia, Paniz Tayaranian Hosseini and Will Crisp. #ESGCT2024 #genetherapy
-
-
We are looking forward to the American Academy of Ophthalmology's Annual Meeting in Chicago this week! Please reach out or stop by Booth 1938 to connect with our team representing Beacon at the meeting. Lance Baldo, Darin Curtiss, Amy Christenson, Amy Adelman House, Ashley Simmons, Benjamin Rice, DO, Marianne Torontali, Ben Novak, Amy Goker, Cheryl Reburiano, JungAh Jung, Rachael Wagner, PhD, Micaela Nee. To learn more about the work we are doing at Beacon to bring transformative ocular gene therapies to patients, please visit https://www.beacontx.com/ #AAO2024 #genetherapy #ophthalmology?
-
-
Beacon is pleased to announce the presentation of 24-month interim results of the Phase 2 SKYLINE trial in patients with X-Linked Retinitis Pigmentosa (XLRP) at the American Academy of Ophthalmology's Annual Meeting in Chicago. XLRP is a blinding rare disease with no available treatment. The 24-month data indicated that AGTC-501 was generally safe and well-tolerated, and showed robust improvements in mean retinal sensitivity. The benefit-risk profile supports on-going clinical development, and we are enrolling our pivotal Phase 2/3 VISTA and open-label Phase 2 DAWN trials for AGTC-501 as we progress toward a potential treatment for patients with XLRP. To read more about the 24-month data from the Phase 2 SKYLINE trial, you can find our press release here: https://lnkd.in/dJsqPrWQ #AAO2024 #ophthalmology #genetherapy #XLRP
-
We hope to see you at the European Society of Retina Specialists (EURETINA) Annual Meeting in Barcelona this week, where Paul Yang, MD, PhD, Chief, Paul H. Casey Ophthalmic Genetics Division, Casey Eye Institute (OHSU),?is presenting 36-Month Interim Results from the Beacon Therapeutics’ Phase 1/2 HORIZON Study on September 19, 15:30 - 15:36 CEST. Thank you to Dr. Yang and to our team representing Beacon at EURETINA. Dr. Lance Baldo, Darin Curtiss, Ashley Simmons, Benjamin Rice, DO, Kathryn Burns, MHA, Amy Perniciaro and Doug Leonard. Please visit https://www.beacontx.com/ to see the presentation and learn more about the work we are doing at Beacon. #EURETINA24 #genetherapy #ophthalmology #retina
-
-
Beacon Therapeutics will present at the Ophthalmology Futures Retina Forum 2024 in Barcelona on September 18th.?You can see our CEO, Lance Baldo, MD and learn more about the work we are doing at Beacon to bring transformative ocular gene therapies to patients.?You can also connect with Lance and the Beacon team at the European Society of Retina Specialists (EURETINA) meeting in Barcelona this week. #genetherapy #EURetina24 #retina #ophthalmology
-
-
We are very pleased to welcome another new executive team member to the Beacon team. Welcome Natasha Jarrett, who joins us as SVP Regulatory Affairs!
-
-
We are thrilled to share that Dr. Lance Baldo has joined Beacon as our new Chief Executive Officer! To learn more about our recent executive appointments, please click the link to the press release below. https://lnkd.in/e823cD5P
-
-
We are excited to welcome Tom Biancardi to the Beacon team as our Chief Financial Officer!
-
-
Today, we announced the appointment of Lance Baldo, MD as CEO, effective August 12, 2024, and Thomas Biancardi as CFO, effective August 1, 2024. Current CEO, David Fellows was named non-Executive Chairman of the Board, effective January 2025. Lance and Tom bring a wealth of experience in biopharmaceuticals and ophthalmology and share our passion to develop potentially transformative ocular gene therapies for patients. We are thankful to Dave for his leadership and excited to welcome Lance and Tom to the Beacon team in August! To learn more about these executive appointments, please click the link to the press release below. https://lnkd.in/e823cD5P
Beacon Therapeutics Appoints Lance Baldo, MD as Chief Executive Officer and Thomas Biancardi as Chief Financial Officer - Beacon Therapeutics
https://www.beacontx.com